HAYA Therapeutics is a clinical-stage precision medicines company spun out of Lausanne University Hospital (CHUV) in 2019. It develops RNA-guided programmable therapeutics that target long non-coding RNAs in the so-called 'dark genome' - the roughly 98% of human DNA that does not code for proteins - to reprogram disease-driving cell states. Its lead candidate, HTX-001, is an antisense oligonucleotide targeting the cardiac lncRNA Wisper for heart failure, with a broader pipeline spanning fibrosis, metabolic disease and cancer. The company is headquartered in Lausanne, Switzerland, with US laboratory operations in San Diego, and raised a $65M Series A in May 2025.
Richard Law is the Chief Business Officer of HAYA Therapeutics, the Lausanne- and San Diego-based biotech decoding the 'dark genome' to build RNA-guided medicines that reprogram disease-driving cell states. A computational chemist turned dealmaker with a Oxford PhD in molecular biophysics and an Imperial MBA, he spent over a decade at Evotec, then steered Exscientia through its 2021 Nasdaq IPO, marquee pharma partnerships, and 2024 merger with Recursion before joining HAYA in March 2025 to drive its partnering strategy and growth.